VIVUS, Inc. (VVUS): Price and Financial Metrics
GET POWR RATINGS... FREE!
VVUS Stock Summary
- VVUS has a higher market value than merely 4.35% of US stocks; more precisely, its current market capitalization is $8,344,214.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -3.65 for Vivus Inc; that's greater than it is for merely 3.86% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VVUS comes in at 585.71% -- higher than that of 98.9% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Vivus Inc, a group of peers worth examining would be KRA, SGMS, ITGR, NH, and NAV.
- VVUS's SEC filings can be seen here. And to visit Vivus Inc's official web site, go to www.vivus.com.
VVUS Stock Price Chart Interactive Chart >
VVUS Price/Volume Stats
|Current price||$0.47||52-week high||$4.75|
|Prev. close||$0.52||52-week low||$0.44|
|Day high||$0.50||Avg. volume||1,441,313|
|50-day MA||$1.00||Dividend yield||N/A|
|200-day MA||$2.08||Market Cap||8.33M|
VIVUS, Inc. (VVUS) Company Bio
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company was founded in 1991 and is based in Mountain View, California.
VVUS Latest News Stream
|Loading, please wait...|
VVUS Latest Social Stream
View Full VVUS Social Stream
Latest VVUS News From Around the Web
Below are the latest news stories about Vivus Inc that investors may wish to consider to help them evaluate VVUS as an investment opportunity.
Vivus (VVUS) plummets 26% premarket after completing the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma will take 100% ownership of the company (the “Prepackaged Plan”), ahead of its Chapter 11 filing.The company solicited IEH as the only holder of claims and has received IEH’s voting in favor of...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharma...
VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing. The Company solicited IEH―as the only holder of claims in classes entitled to vote on the Prepackaged Plan―and has received IEH’s ballots voting in favor of the Prepackaged Plan in accordance with the amended and restated Restructuring Support Agreement executed by the Company and IEH on July 6, 2020.
By John Vandermosten, CFA NASDAQ:VVUS READ THE FULL VVUS RESEARCH REPORT Debt Restructuring In May 2013, Vivus, Inc. (NASDAQ:VVUS) closed offerings of $250 million of 4.5% convertible debt that became due in May 2020. The conversion rate of the notes is 6.73038 per $1,000 of face value leaving them well out of the money and unable to convert. Without conversion, the notes remained as debt and
VIVUS (VVUS) has filed a preliminary prospectus for a public offering of stock and warrants of up to ~$186M. Prices, volumes and terms have yet to be determined.Shares down 3% premarket on light volume....
VVUS Price Returns